A meta-analysis of Early Results to predict Vaccine efficacy against Omicron
Khoury, D. S.; Steain, M.; Triccas, J.; Sigal, A.; Davenport, M. P.; Cromer, D.
Show abstract
In the studies to date, the estimated fold-drop in neutralisation titre against Omicron ranges from 2- to over 20-fold depending on the study and serum tested. Collating data from the first four of these studies results in a combined estimate of the drop in neutralisation titre against Omicron of 9.7-fold (95% CI 5.5-17.1). We use our previously established model to predict that six months after primary immunisation with an mRNA vaccine, efficacy for Omicron is estimated to have waned to around 40% against symptomatic and 80% against severe disease. A booster dose with an existing mRNA vaccine (even though it targets the ancestral spike) has the potential to raise efficacy for Omicron to 86.2% (95% CI: 72.6-94) against symptomatic infection and 98.2% (95% CI: 90.2-99.7) against severe infection.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 93%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 93%
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 92%
Similar papers in this journal
- Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England 94%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 94%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 93%
Similar papers in this journal
- Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England 94%
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera 93%
- Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory 92%
Similar papers in this journal
- Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection 97%
- Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers 94%
- International risk of the new variant COVID-19 importations originating in the United Kingdom 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.